Table 1. Biological and technical features of the HLDA10-DC monoclonal antibody reagents tested on normal human PB DC and monocyte subsets.

Specificity	Target molecule	Clone	Antibody (workshop codes)	Reactivity
C-type lectins	CD302	FAB637P	10–54	mDCd+, cMo+, iMo−/+, ncMod+
	CD367	FAB1748P	10–13	mDC+++, cMo++, iMo+, ncMod+
	CD367	111F8.04	10–71	mDC++, pDCd+, cMo++, iMo++, ncMo+
	CD367	9E8	10–72	mDC+, cMo++, iMo++, ncMod+
	CD368	FAB2806P	10–21	cMo++
	CD368	9B9	10–78	cMo++, iMo+
	CD369	GE2	10–01	−
	CD369	FAB1859P	10–35	cMo+, iMo+, ncMod+
	CD369	15 E 2	10–79	cMo++, iMo++, ncMo+
	CD370	8F9	10–02	−
	CD370	9A11	10–09	−
	CD370	FAB6049P	10–45	−
	CD370	8F9	10–65	iMo+
	CD371	HB3	10–17	mDC+++, cMo++, iMo++, ncMo+
	CD371	FAB2946P	10–51	mDC++, cMo+, iMo++, ncMo+
	CD371	50C1	10–73	mDC+++, pDCd+, cMo++, iMo++, ncMo++
	Clec2D	FAB3480P	10–06	−
	Clec5A	FAB238P	10–28	cMo+
	Clec5C	FAB1900P	10–31	−
	Clec8A	FAB1798P	10–40	−
	Clec14A	FAB7436P	10–57	−
T-cell co stimulatory inhibitory molecules	CD101	BB27	10–34	mDC+++, cMo++, iMo++, ncMo++
	CD245	DY12	10–43	−
	CD245	DY35	10–48	−
	CD273	ANC8D12	10–61	−
	CD365	FAB1750P	10–14	−
	CD365	1D12	10–67	−
	CD366	FAB2365P	10–24	mDC++, cMo+, iMo++, ncMod+
	CD366	F38–2E2	10–75	mDC−/+, cMod+, iMod+, ncMod+
	ULBP-3	FAB1517P	10–52	mDC+, iMo+
	B7-H4	MIH43	10–64	−
	TSLP-R	1B4	10–68	−
	TIM4	9F4	10–81	−
DC-related markers	CD1a	010e	10–03	−
	CD1a	0619	10–10	−
	CD1b	O249	10–18	−
	CD1c	L161	10–26	−
	CD85g	17G10.2	10–66	pDC+++
	CD85h	24	10–74	mDC++, cMo++, iMo++, ncMo+
	CD209	118A8.05	10–83	−
Phagocytic-related molecules	FPRL1/FPRL2	FAB3479P	10–36	cMo+, iMo++
	FPR1	FAB3744P	10–47	mDCd+, cMod+, iMo−/+, SLAN−ncMod+
	Calreticulin	FMU-CRT-2	10–23	−
	Calreticulin	FMU-CRT-8	10–29	−
	Calreticulin	FMU-CRT-17	10–42	−
Myeloid markers	MAIR II	TX45	10–80	mDCd+, cMo++, iMo++, ncMod+
	TREM2	FAB17291P	10–07	cMo++, iMo++, SLAN+ncMod+
	FDF03	36H2	10–84	-
Chemokine and cytokine receptors	CD135	FAB812P	10–15	mDC++
	CD195	HEK/1/85	10–76	mDC+++, pDC++, iMod+
	CD213a2/ IL13Ra2	FMU-IL-13RA2–7	10–30	−
	CD213a2/ IL13Ra2	FMU-IL-13RA2–8	10–37	−
	CD213a2/ IL13Ra2	FMU-IL-13RA2–14	10–41	−
Other molecules (miscelanea)	Tie-2	FAB3131P	10–56	−
	P2X7	L4	10–70	mDC+, cMo+, iMo++, SLAN− ncMo++, SLAN+ ncMo+
	LPAP	CL3	10–04	−
	LPAP	CL4	10–11	−
	LPAP	CL7	10–19	−
	FAT1 cadherin	FMU-FAT-6	10–08	−
Other molecules (miscelanea)	FAT1 cadherin	FMU-FAT1–7	10–16	−
	unknown	BGA69	10–38	−
	Axl	FAB154P	10–50	−
	IL-1RAcP	AY19	10–53	−
	Vimentin	SC5	10–55	−
	unknown	MDR64	10–59	−
	unknown	CMRF-44	10–82	−
	GARP	ANC8C9	10–62	−
	GARP	ANC10G10	10–63	−
	unknown	CMRF-56	10–69	−
	DORA	104A10.01	10–77	−
	Tetanus toxoid	CMRF-81	10–85	−

Abbreviations: cMo, classical monocytes; iMo, intermediate monocytes; mDCs, myeloid dendritic cells; ncMo, non-classical monocytes; pDCs, plasmacytoid dendritic cells;.

Reactivity for each cell population is displayed as superscripts; symbols used for the assessment of the expression are based on median values of fluorescence intensity:−(negative); −/+ (variable reactivity, from negative to positive); d+ (dim positive);+(positive); ++ (strong positive); +++ (very strong positive). Peripheral blood cell subsets other than APCs were used as internal controls, to establish the cutoff for positivity per marker/monoclonal antibody reactivity.